Just over a month ago, one of the most interesting and potentially consequential hearings in the history of US cannabis policy began.
Over the next 17 days, with the global cannabis industry watching closely, the Drug Enforcement Administration (DEA) made a convincing, science-led case that cannabis does indeed have legitimate medical uses for a range of conditions.
As the rescheduling process slows back to stasis while Administrative Law Judge Derek Julius considers his ultimately non-binding recommendation, the wake of this unprecedented federal shift in attitudes towards cannabis is beginning to be felt throughout the entire ecosystem.
For Adam Stettner, founder and Chief Executive Officer of FundCanna, a San Diego-based lending platform that has committed more than US$550 million to cannabis operators across more than 5,000 transactions since 2021, the shift is already visible.
“In the last two, three months we’re seeing a higher application rate and higher velocity in the cycling of the money – people are buying more, paying down faster and redrawing sooner,’ he told Business of Cannabis. “We’re seeing faster early repay followed by immediate redraws. To me, that’s a sign of more certainty among our client base.”
A ‘pleasant surprise’
The most obvious shift has been the apparent 180 degree turn of the DEA, which surprised even veterans like Stettner in defending their position that cannabis should be classified as a Schedule III drug under the Controlled Substances Act (CSA)
“To have the federal government, which for over 50 years treated cannabis like heroin, to then spend two and a half weeks outlining all the reasons why it’s nothing like heroin, was a nice upside,” he said. “I was pleasantly surprised from the beginning. And that never changed.”
On the other side of the bench, the arguments against rescheduling put forward by the seven ‘affected’ parties were at best lacklustre, retreading tired arguments that have been the staple of cannabis opponents for years.
“It felt like a lot of last gasp and very little scientific or compelling evidence as to why anyone should oppose the reschedule,” Stettner continued. “A lot of what was stated was kind of absurd. Not refuting any of the scientific evidence, but more like: hey, this will cause economic harm to people that do drug testing. That’s not a reason to keep something in Schedule I.”
While acknowledging that this is just the first step in a process likely to continue through the coming months and even years, Stettner illustrated the absurdity of the current state of affairs.
“Cannabis, as you and I sit here right now, as a product, as a crop that is grown, is both Schedule I and Schedule III. How you use the product dictates whether it’s Schedule I or Schedule III. And I don’t know of any other product that is treated that way.”
He drew a contrast with Tylenol with codeine, a Schedule III drug that retains that classification regardless of how a particular user came to possess it. Cannabis offers no equivalent clarity. “This might be the first time in my adult life where one product is bifurcated between Schedule I and Schedule III,” he added.
With this in mind, he explained that the real question posed by the DEA hearing was not whether adult-use should follow medical cannabis into Schedule III, but whether cannabis as a whole meets that criteria.
READ MORE…
Beyond 280E
The financial implication most widely cited in rescheduling coverage is the potential end of IRC Section 280E, the federal provision that prevents plant-touching businesses from deducting ordinary operating expenses on the basis that their activity remains federally prohibited.
According to analysis by Whitney Economics published in April 2026, cannabis operators paid an estimated $2.24bn in excess federal taxes in 2025 as a direct result of 280E.
However, as Stettner notes: “280E is the headline.” From it, a cascade of changes to these operators balance sheets flows, which is where the real change will be felt.
“It then trickles into the financial strength of an organisation and their balance sheet and their ability to fund their operations versus having their money locked up in pending tax bills,” he explained.
“The effective tax rate being 70% to 80% when you can’t deduct your costs, relative to, let’s say, low 20s when you can, that right away frees up cash flow. These balance sheets look unnecessarily weak. They’re weaker than they actually are because of their tax rate.”
FundCanna already normalises 280E out of its credit analysis. What changes post-rescheduling is that this underlying financial strength becomes visible to a broader pool of capital. “Every organisation will instantly look healthier because their balance sheet will look better, which either frees up more capital for debt service, meaning we can write larger or longer-duration paper.”
In turn, this will change the behaviour of the operators, rather than simply making them more attractive on paper to potential investors.
“It opens up a lot more opportunities for scale and growth, for acquisition, for expansion. Because you have more free cash flow, you want to reinvest. How do you then accelerate that? You do it with leverage. And that’s where FundCanna sits.”
Three conditions, in order
Rescheduling, for all its benefits and as yet unknown effects on the sector at large, is not a panacea. Fundamental issues like banking and payment processing still leave US operators on the back foot in comparison to almost every other industry.
According to the latest figures from the Financial Crimes Enforcement Network (FinCEN), as of December 2024 just under 1000 banks (816 banks and 182 credit unions) currently service the cannabis industry as deposit institutions, around 10% of all US banks and credit unions.
Rescheduling alone will not move that figure substantially, Stettner believes, because the foundational issue is not scheduling but FinCEN guidance. Its 2014 framework for cannabis-related suspicious activity reporting remains unchanged by the Schedule III order, meaning the compliance burden on banks that serve cannabis operators is identical today to what it was before April.
“Without the SAFE Banking Act and without FinCEN guidance, I don’t think we’ll get much in the way of movement, although we will get much more curiosity,” he said. “With FinCEN guidance, I think we’ll see movement. And with SAFE Banking’s passage, I think you’ll see much more broad or widespread movement and clarity… I think you’ll see more credit unions, more regionals start to take a look, or maybe selectively bank the industry.”
He sets realistic expectations, though, caveating this optimism by suggesting large institutions like JP Morgan won’t ‘rush in’.
Traditional small and medium-sized businesses like restaurants, dry cleaners and contractors are declined by banks 75% to 80% of the time without any federal prohibition on their activity, he explained. As such, we should ‘never expect that this industry is going to be serviced at a widespread level, because it’s always going to be a vice industry. A non-vice, never-illicit industry is still underserved three quarters of the time.’
Should the newly reintroduced SAFE Banking Act of 2026 pass on its eighth attempt, it could shift the moratorium on cannabis transactions held by almost every card network in a way that rescheduling or FinCEN guidance cannot.
The market remains cautious
Despite the meaningful progress made in shifting federal cannabis policy over the last year, alongside the emerging spate of uplistings to major exchanges, cannabis stocks have failed to follow.
Stettner, one of the industry’s most experienced investors, observed: “Since the executive order, they’re flat to down. Movement to Schedule III, they’re flat to down. Since the hearing began, they’re flat to down. Since you’ve seen two public companies uplist, they’re both down post-uplisting.”
His conclusion is that this represents opportunity rather than a signal to exit. Price to earnings ratios for even the most profitable companies remain ‘very low’.
Being careful to frame this as analysis, not advice, he said: “I think the industry is undervalued now. In 2019, I think it was overvalued.”
Compared to the industry as it stands, the 2019 capital surge had fewer legal states, no meaningful regulatory momentum, no federal pathway, and yet ‘people were piling into space.’
“I made a conscious decision to leave the non-cannabis industry and enter this industry because I saw an opportunity,’ he concluded. “It was far enough along that it wasn’t going to reverse course. But early enough that we still had a lot of upside ahead of us. Five years on, that opportunity is greater today than it was then.”







